• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • Our Technology
      • TIM
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Cardio3 BioSciences to raise capital via a private placement of new shares

February 26, 2016 By Celyad

Mont-Saint-Guibert, Belgium – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, announces today the launch of a private placement of new ordinary shares to institutional investors. Cardio3 BioSciences intends to raise up to a maximum of 713,380 new shares (10% of the current share capital).

The new shares will be offered through a book-building procedure with institutional investors in Belgium and abroad. The Board of Directors has decided to waive the preferential subscription rights of the existing shareholders in the framework of this transaction with respect to the issuance of the new shares. The capital increase will take place within the limits of the authorised share capital as set out in the Company’s articles of association and in accordance with Article 604 of the Belgian Company Code.

The Company intends to use the proceeds from the proposed private placement to advance its product development efforts and for general working capital purposes. It may in the future consider additional financing transactions to fund its operations, which may include strategic transactions or additional private placement transactions or public offerings of securities.

The placement will start today, Thursday, 26 of February 2015, immediately following this announcement

UBS Investment Bank will be acting as Global Coordinator and Bookrunner for the offering. Bryan, Garnier & Co and Petercam will act as Placement Agents.

The precise number of new shares to be issued and the subscription price per new share will be agreed by the Company and the Global Coordinator and the Placement Agents at the close of the bookbuilding process and the results of the placement will be announced as soon as practicable thereafter.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Regulated

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use